Herpes simplex virus infections remain a serious global health problem and are the leading cause of genital ulcer disease, a major co-factor in the HIV epidemic, and associated with significant morbidity and mortality in newborns born to mothers who are infected. In a recent publication in eLife, Drs. William Jacobs and Betsy Herold of the Albert Einstein College of Medicine have taken a giant step toward developing a viable herpes vaccine. 

X-VAX Technology

X-VAX Technology, Inc.

X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program

Peer-review Articles on the HSV-2 ΔgD vaccine

eLife

JCI Insight

The Journal of Infectious Diseases

News articles on the elife PUBLICATION

Featured
Experimental herpes vaccine works in mice
Experimental herpes vaccine works in mice
Virology: Ups and downs in the search for a Herpes simplex virus vaccine
Virology: Ups and downs in the search for a Herpes simplex virus vaccine
Experimental Herpes Vaccine Upends Traditional Approach and Shows Promise
Experimental Herpes Vaccine Upends Traditional Approach and Shows Promise
Radical Vaccine Design Effective Against Herpes Viruses
Radical Vaccine Design Effective Against Herpes Viruses
Vaccine Design Effective Against Herpes Viruses
Vaccine Design Effective Against Herpes Viruses